Loading clinical trials...

Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity

NCT06771115•Zomagen Biosciences Ltd.

View on ClinicalTrials.gov

Summary

This is a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide. This study consists of a 30-day Screening Period (to see if a participant qualifies for a study), a 12-week double-blind treatment period (a participant receives VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide), and a 30-day Follow-Up Period. The maximum duration of treatment will be approximately 12 weeks.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participants are male or female ≥ 18 years up to ≤ 80 years of age.
•Ability to comply with study requirements.
•BMI ≥ 30.0 to ≤ 42.0 kg/m2 at screening.
•Stable body weight (± 5%) for at least 3 months prior to screening.
•hs-CRP ≥ 2 mg/L at screening.
•Hypertension or hyperlipidemia which are known to be associated with increased risk of cardiovascular events, if present, must be controlled with stable dose/therapy.
•History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion Criteria

•Obesity induced by endocrinologic disorders, or diagnosed genetic or syndromic forms of obesity
•Have any prior diagnosis of diabetes mellitus
•Current participation (or within the last 3 months) in an organized weight reduction program.
•History or presence of clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility, have undergone prior surgical treatment for obesity (e.g., gastric bypass \[bariatric\] surgery or restrictive bariatric surgery), or have an endoscopic and/or device-based therapy for obesity.
•Clinically relevant medical condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult.
•Use of any medication (e.g., GLP-1 agonists), nutritional supplement, or over the counter product for weight loss within the previous 6 months or during study participation, unless administered as a part of assigned study treatment in this study.
•Receipt of the following medications:
•1. Any immunosuppressive biologic or targeted therapy within 90 days prior to Day 1.
•2. Use of anti-inflammatory medications within 30 days prior to Day 1
•3. Colchicine within 30 days prior to Day 1.
+1 more criteria

Locations (14)

840005

Birmingham, Alabama, United States

840003

Lake Forest, California, United States

840011

Long Beach, California, United States

840001

Largo, Florida, United States

840012

Ocoee, Florida, United States

840016

Port Orange, Florida, United States

840014

Newton, Kansas, United States

840015

Marrero, Louisiana, United States

840017

Marrero, Louisiana, United States

840002

Austin, Texas, United States

Key Dates

Start Date

January 7, 2025

Primary Completion Date

September 10, 2025

Completion Date

September 10, 2025

Last Updated

November 10, 2025

Enrollment

176

ACTUAL participants

Conditions

Obesity

Interventions

VTX3232 Dose A

DRUG

Placebo

DRUG

VTX3232 Dose A in combination with semaglutide

DRUG

Placebo in combination with semaglutide

DRUG

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

RECRUITING

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 10, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

Inclusion Criteria

Exclusion Criteria

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Protein Supplementation Intervention on Body Weight

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss